TY  - GEN
AU  - Lukas,Martin
AU  - Malickova,K
AU  - Kolar,M
AU  - Bortlik,M
AU  - Vasatko,M
AU  - Machkova,N
AU  - Hruba,V
AU  - Duricova,D
AU  - Lukas,Milan
TI  - Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
SN  - 1876-4479
PY  - 2021///0615
KW  - Adalimumab
KW  - blood
KW  - Adult
KW  - Antibodies
KW  - Biosimilar Pharmaceuticals
KW  - C-Reactive Protein
KW  - metabolism
KW  - Colitis, Ulcerative
KW  - Crohn Disease
KW  - Drug Substitution
KW  - Feces
KW  - chemistry
KW  - Female
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Leukocyte L1 Antigen Complex
KW  - analysis
KW  - Male
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Severity of Illness Index
KW  - Tertiary Care Centers
KW  - Treatment Outcome
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1093/ecco-jcc/jjaa001
ER  -